Claudia Collà Ruvolo1, Luigi Nocera2, L Franziska Stolzenbach3, Mike Wenzel4, Vito Cucchiara5, Zhe Tian6, Shahrokh F Shariat7, Fred Saad6, Nicola Longo8, Francesco Montorsi9, Alberto Briganti9, Vincenzo Mirone8, Pierre I Karakiewicz6. 1. Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada; Department of Neurosciences, Reproductive Sciences and Odontostomatology, Urology Unit, University of Naples Federico II, Naples, Italy. Electronic address: c.collaruvolo@gmail.com. 2. Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada; Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IBCAS San Raffaele Scientific Institute, Milan, Italy. 3. Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada; Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany. 4. Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada; Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany. 5. Department of Neurosciences, Reproductive Sciences and Odontostomatology, Urology Unit, University of Naples Federico II, Naples, Italy; Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IBCAS San Raffaele Scientific Institute, Milan, Italy. 6. Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada. 7. Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, NY, USA; Department of Urology, University of Texas Southwestern, Dallas, TX, USA; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic; Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia; Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan. 8. Department of Neurosciences, Reproductive Sciences and Odontostomatology, Urology Unit, University of Naples Federico II, Naples, Italy. 9. Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IBCAS San Raffaele Scientific Institute, Milan, Italy.
Abstract
BACKGROUND: Contemporary incidence and mortality rates of upper tract urothelial carcinoma (UTUC) are unavailable. OBJECTIVE: To describe contemporary UTUC incidence and mortality rates in the USA. DESIGN, SETTING, AND PARTICIPANTS: Within the Surveillance, Epidemiology and End Results (SEER) database (2004-2016), we identified 13 075 UTUC patients. Of all, 9208 (70.4%) harbored nonmetastatic UTUC and were treated with radical nephroureterectomy versus 1174 (9.0%) who harbored metastatic UTUC. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Age-standardized incidence rates per 100 000 person years were calculated. Kaplan-Meier curves and multivariable Cox regression models addressed cancer-specific and overall mortality. RESULTS AND LIMITATIONS: Overall UTUC age-standardized incidence rates decreased from 1.3 to 1.1 cases per 100 000 person years (average annual percentage change: -1.32%, p = 0.002). Moreover, age-standardized incidence rates decreased for T1-2N0M0 (average annual percentage change: -2.77%, p < 0.001) but increased for T1-4N0-2M1 stage (average annual percentage change: +2.87%, p < 0.01). In nonmetastatic UTUC treated with radical nephroureterectomy, stage, grade, age, and sex (p < 0.001) were independent predictors in multivariable Cox regression models focusing on cancer-specific mortality. In metastatic UTUC, chemotherapy administration, radical nephroureterectomy treatment, and ureteral primary were independent predictors of lower overall mortality in multivariable Cox regression models. CONCLUSIONS: Although overall incidence of UTUC decreased, the incidence of metastatic UTUC increased over the study period. The majority of nonmetastatic UTUC harbored T1N0M0 stage. However, T3N0M0, T4N0M0, and T1-4N1-2M0 stages, respectively, affected 28.9%, 4.6%, and 10.0% of all incident cases. In metastatic UTUC, both chemotherapy and radical nephroureterectomy use exerted an important protective effect on overall mortality, and ureteral primaries exhibited more favorable survival. PATIENT SUMMARY: From 2004 to 2016, the incidence of upper tract urothelial carcinoma decreased in the USA. However, more advanced stages are on the rise.
BACKGROUND: Contemporary incidence and mortality rates of upper tract urothelial carcinoma (UTUC) are unavailable. OBJECTIVE: To describe contemporary UTUC incidence and mortality rates in the USA. DESIGN, SETTING, AND PARTICIPANTS: Within the Surveillance, Epidemiology and End Results (SEER) database (2004-2016), we identified 13 075 UTUC patients. Of all, 9208 (70.4%) harbored nonmetastatic UTUC and were treated with radical nephroureterectomy versus 1174 (9.0%) who harbored metastatic UTUC. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Age-standardized incidence rates per 100 000 person years were calculated. Kaplan-Meier curves and multivariable Cox regression models addressed cancer-specific and overall mortality. RESULTS AND LIMITATIONS: Overall UTUC age-standardized incidence rates decreased from 1.3 to 1.1 cases per 100 000 person years (average annual percentage change: -1.32%, p = 0.002). Moreover, age-standardized incidence rates decreased for T1-2N0M0 (average annual percentage change: -2.77%, p < 0.001) but increased for T1-4N0-2M1 stage (average annual percentage change: +2.87%, p < 0.01). In nonmetastatic UTUC treated with radical nephroureterectomy, stage, grade, age, and sex (p < 0.001) were independent predictors in multivariable Cox regression models focusing on cancer-specific mortality. In metastatic UTUC, chemotherapy administration, radical nephroureterectomy treatment, and ureteral primary were independent predictors of lower overall mortality in multivariable Cox regression models. CONCLUSIONS: Although overall incidence of UTUC decreased, the incidence of metastatic UTUC increased over the study period. The majority of nonmetastatic UTUC harbored T1N0M0 stage. However, T3N0M0, T4N0M0, and T1-4N1-2M0 stages, respectively, affected 28.9%, 4.6%, and 10.0% of all incident cases. In metastatic UTUC, both chemotherapy and radical nephroureterectomy use exerted an important protective effect on overall mortality, and ureteral primaries exhibited more favorable survival. PATIENT SUMMARY: From 2004 to 2016, the incidence of upper tract urothelial carcinoma decreased in the USA. However, more advanced stages are on the rise.
Authors: Z H Li; C R Xu; Y Liu; H Guan; M Zhang; X Y Che; Q Tang; Y B Huang; X S Li; L Q Hou Journal: Beijing Da Xue Xue Bao Yi Xue Ban Date: 2022-08-18
Authors: Katherine E Fero; Yong Shan; Patrick M Lec; Vidit Sharma; Aditya Srinivasan; Giri Movva; Jacques Baillargeon; Karim Chamie; Stephen B Williams Journal: JNCI Cancer Spectr Date: 2021-10-01
Authors: Gianluigi Califano; Idir Ouzaid; Paul Laine-Caroff; Arthur Peyrottes; Claudia Collà Ruvolo; Benjamin Pradère; Vincent Elalouf; Vincent Misrai; Jean-François Hermieu; Shahrokh F Shariat; Evanguelos Xylinas Journal: Curr Oncol Date: 2022-01-29 Impact factor: 3.677
Authors: Arthur Peyrottes; Gianluigi Califano; Idir Ouzaïd; Paul Lainé-Caroff; Thibaut Long Depaquit; Jean-François Hermieu; Evanguelos Xylinas Journal: Front Surg Date: 2022-03-24
Authors: Maximilian Pallauf; Frederik König; David D'Andrea; Ekaterina Laukhtina; Hadi Mostafaei; Reza Sari Motlagh; Fahad Quhal; Abdulmajeed Aydh; Takafumi Yanagisawa; Tatsushi Kawada; Pawel Rajwa; Lukas Lusuardi; Francesco Soria; Pierre I Karakiewicz; Morgan Rouprêt; Michael Rink; Yair Lotan; Vitaly Margulis; Nirmish Singla; Evanguelos Xylinas; Shahrokh F Shariat; Benjamin Pradere Journal: Front Oncol Date: 2022-07-01 Impact factor: 5.738
Authors: Claudia Collà Ruvolo; Christoph Würnschimmel; Mike Wenzel; Luigi Nocera; Giuseppe Celentano; Francesco Mangiapia; Zhe Tian; Shahrokh F Shariat; Fred Saad; Felix H C Chun; Alberto Briganti; Nicola Longo; Vincenzo Mirone; Pierre I Karakiewicz Journal: Int J Clin Oncol Date: 2021-06-06 Impact factor: 3.402